172 related articles for article (PubMed ID: 37294384)
41. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
[TBL] [Abstract][Full Text] [Related]
42. [The efficacy and prognostic factors of immunotherapy in advanced non-small cell lung cancer patients with different driver gene mutations].
Ma SX; Ma N; Han J; He Z; Wang L; Wang Q
Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(13):922-929. PubMed ID: 35385963
[No Abstract] [Full Text] [Related]
43. Distinct clinicopathologic characteristics of lung mucinous adenocarcinoma with KRAS mutation.
Ichinokawa H; Ishii G; Nagai K; Kawase A; Yoshida J; Nishimura M; Hishida T; Ogasawara N; Tsuchihara K; Ochiai A
Hum Pathol; 2013 Dec; 44(12):2636-42. PubMed ID: 24119562
[TBL] [Abstract][Full Text] [Related]
44. Association between the novel classification of lung adenocarcinoma subtypes and EGFR/KRAS mutation status: A systematic literature review and pooled-data analysis.
Jiang L; Mino-Kenudson M; Roden AC; Rosell R; Molina MÁ; Flores RM; Pilz LR; Brunelli A; Venuta F; He J;
Eur J Surg Oncol; 2019 May; 45(5):870-876. PubMed ID: 30833014
[TBL] [Abstract][Full Text] [Related]
45. Frequency of EGFR and KRAS mutations in Japanese patients with lung adenocarcinoma with features of the mucinous subtype of bronchioloalveolar carcinoma.
Hata A; Katakami N; Fujita S; Kaji R; Imai Y; Takahashi Y; Nishimura T; Tomii K; Ishihara K
J Thorac Oncol; 2010 Aug; 5(8):1197-200. PubMed ID: 20661086
[TBL] [Abstract][Full Text] [Related]
46. Prognostic Value of KRAS Mutation Subtypes and PD-L1 Expression in Patients With Lung Adenocarcinoma.
Tao L; Miao R; Mekhail T; Sun J; Meng L; Fang C; Guan J; Jain A; Du Y; Allen A; Rzeszutko BL; Socinski MA; Chang CC
Clin Lung Cancer; 2021 Jul; 22(4):e506-e511. PubMed ID: 32807653
[TBL] [Abstract][Full Text] [Related]
47. Primary Invasive Mucinous Adenocarcinoma of the Lung: Prognostic Value of CT Imaging Features Combined with Clinical Factors.
Wang T; Yang Y; Liu X; Deng J; Wu J; Hou L; Wu C; She Y; Sun X; Xie D; Chen C
Korean J Radiol; 2021 Apr; 22(4):652-662. PubMed ID: 33236544
[TBL] [Abstract][Full Text] [Related]
48. Postoperative survival of pulmonary invasive mucinous adenocarcinoma versus non-mucinous invasive adenocarcinoma.
Cui D; Xie S; Liu Q
BMC Pulm Med; 2023 Jan; 23(1):9. PubMed ID: 36624430
[TBL] [Abstract][Full Text] [Related]
49. KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma.
Kadota K; Sima CS; Arcila ME; Hedvat C; Kris MG; Jones DR; Adusumilli PS; Travis WD
Am J Surg Pathol; 2016 Dec; 40(12):1579-1590. PubMed ID: 27740967
[TBL] [Abstract][Full Text] [Related]
50. Presence of non-Newtonian fluid in invasive pulmonary mucinous adenocarcinomas impacts fluorescence during intraoperative molecular imaging of lung cancer.
Azari F; Kennedy G; Chang A; Nadeem B; Sullivan N; Marfatia I; Din A; Desphande C; Kucharczuk J; Delikatny EJ; Singhal S
Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4406-4418. PubMed ID: 35876868
[TBL] [Abstract][Full Text] [Related]
51. FOXA2 Cooperates with Mutant KRAS to Drive Invasive Mucinous Adenocarcinoma of the Lung.
Tomoshige K; Stuart WD; Fink-Baldauf IM; Ito M; Tsuchiya T; Nagayasu T; Yamatsuji T; Okada M; Fukazawa T; Guo M; Maeda Y
Cancer Res; 2023 May; 83(9):1443-1458. PubMed ID: 37067057
[TBL] [Abstract][Full Text] [Related]
52. Pulmonary invasive mucinous adenocarcinoma.
Chang WC; Zhang YZ; Nicholson AG
Histopathology; 2024 Jan; 84(1):18-31. PubMed ID: 37867404
[TBL] [Abstract][Full Text] [Related]
53. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose.
Li H; Pan Y; Li Y; Li C; Wang R; Hu H; Zhang Y; Ye T; Wang L; Shen L; Sun Y; Chen H
Lung Cancer; 2013 Jan; 79(1):8-13. PubMed ID: 23098378
[TBL] [Abstract][Full Text] [Related]
54. GATA6-positive lung adenocarcinomas are associated with invasive mucinous adenocarcinoma morphology, hepatocyte nuclear factor 4α expression, and KRAS mutations.
Nakajima N; Yoshizawa A; Nakajima T; Hirata M; Furuhata A; Sumiyoshi S; Rokutan-Kurata M; Sonobe M; Menju T; Miyamoto E; Chen-Yoshikawa TF; Date H; Haga H
Histopathology; 2018 Jul; 73(1):38-48. PubMed ID: 29469192
[TBL] [Abstract][Full Text] [Related]
55. Retrospective Multicenter Study Investigating the Role of Targeted Next-Generation Sequencing of Selected Cancer Genes in Mucinous Adenocarcinoma of the Lung.
Righi L; Vatrano S; Di Nicolantonio F; Massa F; Rossi G; Cavazza A; Volante M; Votta A; Izzo S; Lo Iacono M; Ardissone F; Di Maio M; Novello S; Scagliotti GV; Papotti M
J Thorac Oncol; 2016 Apr; 11(4):504-15. PubMed ID: 26774193
[TBL] [Abstract][Full Text] [Related]
56. Optimizing palliative chemotherapy for advanced invasive mucinous adenocarcinoma of the lung.
Jang YJ; Hyun DG; Choi CM; Lee DH; Kim SW; Yoon S; Kim WS; Ji W; Lee JC
BMC Cancer; 2021 Jun; 21(1):731. PubMed ID: 34174841
[TBL] [Abstract][Full Text] [Related]
57. Prognostic impact of mucin spread, tumor cell spread, and invasive size in invasive mucinous adenocarcinoma of the lung.
Saito T; Tsuta K; Honda O; Ishida M; Yamaka R; Tanaka N; Ishida K; Utsumi T; Maru N; Matsui H; Taniguchi Y; Hino H; Kurata T; Murakawa T
Lung Cancer; 2020 Aug; 146():50-57. PubMed ID: 32512273
[TBL] [Abstract][Full Text] [Related]
58. Mucinous Adenocarcinoma With Intrapulmonary Metastasis Harboring KRAS and GNAS Mutations Arising in Congenital Pulmonary Airway Malformation.
de Cordova XF; Wang H; Mehrad M; Eisenberg R; Johnson J; Wei Q; Borinstein S; Danko ME; Liang J
Am J Clin Pathol; 2021 Jul; 156(2):313-319. PubMed ID: 33609098
[TBL] [Abstract][Full Text] [Related]
59. [Relevance of molecular alterations in histopathologic subtyping of lung adenocarcinoma based on 2011 International Multidisciplinary Lung Adenocarcinoma Classification].
Liu B; Shi SS; Wang X; Xu Y; Zhang XH; Yu B; Lu ZF; Wang JD; Zhou XJ
Zhonghua Bing Li Xue Za Zhi; 2012 Aug; 41(8):505-10. PubMed ID: 23157740
[TBL] [Abstract][Full Text] [Related]
60. Endometrial Adenocarcinomas With Significant Mucinous Differentiation: A Characterization of Intratumoral Heterogeneity of KRAS Mutations in Mucinous and Endometrioid Histologic Components.
Jackson CL; Hang S; Hansen K; He M; Sung CJ; Quddus MR; Xiong M; Wang Y; Patel NR; Lawrence WD; Xiong J
Int J Gynecol Cancer; 2018 Feb; 28(2):241-247. PubMed ID: 29303928
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
